KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Average (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Equity Average for 6 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 39.66% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 39.66%, and an annual FY2025 reading of $1.1 billion, up 44.55% over the prior year.
  • Equity Average was $1.1 billion for Q4 2025 at Recursion Pharmaceuticals, up from $983.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.1 billion in Q4 2025 and bottomed at -$219.7 million in Q1 2021.
  • Average Equity Average over 5 years is $553.2 million, with a median of $479.2 million recorded in 2022.
  • The sharpest move saw Equity Average skyrocketed 463.6% in 2021, then crashed 33.51% in 2022.
  • Year by year, Equity Average stood at $571.0 million in 2021, then decreased by 23.48% to $436.9 million in 2022, then increased by 3.15% to $450.7 million in 2023, then skyrocketed by 72.99% to $779.7 million in 2024, then surged by 39.66% to $1.1 billion in 2025.
  • Business Quant data shows Equity Average for RXRX at $1.1 billion in Q4 2025, $983.0 million in Q3 2025, and $926.5 million in Q2 2025.